Polynovo (FRA:MFJ) Debt-to-Equity : 0.22 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Polynovo Debt-to-Equity?

Polynovo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.00 Mil. Polynovo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €8.41 Mil. Polynovo's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €42.38 Mil. Polynovo's debt to equity for the quarter that ended in Dec. 2023 was 0.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Polynovo's Debt-to-Equity or its related term are showing as below:

FRA:MFJ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.42 Max: 0.62
Current: 0.22

During the past 13 years, the highest Debt-to-Equity Ratio of Polynovo was 0.62. The lowest was 0.10. And the median was 0.42.

FRA:MFJ's Debt-to-Equity is ranked worse than
50.84% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs FRA:MFJ: 0.22

Polynovo Debt-to-Equity Historical Data

The historical data trend for Polynovo's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo Debt-to-Equity Chart

Polynovo Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.42

0.45

0.62

0.25

Polynovo Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.54	0.62	0.28	0.25	0.22

Competitive Comparison of Polynovo's Debt-to-Equity

For the Medical Devices subindustry, Polynovo's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Polynovo's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Polynovo's Debt-to-Equity falls into.

Polynovo Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Polynovo's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.171	+	8.768)	/	40.502
	=	0.25

Polynovo's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.003	+	8.407)	/	42.383
	=	0.22

Polynovo (FRA:MFJ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Polynovo Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Polynovo's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Polynovo (FRA:MFJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (FRA:MFJ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CALZF:USA PNV:Australia

Address

320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207

Website

https://www.polynovo.com

Polynovo earns most of its revenue from U.S. sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Polynovo (FRA:MFJ) Headlines

No Headlines